
CAPVAXIVE Demonstrates Immune Protection in At-Risk Youth
Merck, known as MSD outside of the United States and Canada, announced significant new findings from its Phase 3 STRIDE-13 clinical trial of CAPVAXIVE® (pneumococcal 21-valent conjugate vaccine). The results, presented at the 6th European Society of Clinical Microbiology and…












